RecruitingMetabolic Dysfunction-associated Steatohepatitis
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Eligible age
18–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.
Sponsor: GlaxoSmithKline
You may qualify if…
- ✓ Participants aged between 18 and 75 years at enrollment.
- ✓ Participants with compensated cirrhosis due to MASH, confirmed by non-invasive assessments.
- ✓ Participants with history or presence of at least two components of metabolic syndrome.
You may not qualify if…
- ✕ Participants with other chronic liver diseases.
- ✕ Participants with evidence or history of decompensated liver disease or hepatocellular carcinoma.
- ✕ Participants with history of Type 1 diabetes mellitus or major Type 2 diabetes complications.
- ✕ Participants with history or evidence of chronic pancreatic disease; pancreatic injury or acute pancreatitis within 6 months before screening.
- ✕ Participants with a recent history or planned surgical procedures or medications intended to produce significant weight loss.
- ✕ Participants with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>=5 times upper limit normal (ULN).
- ✕ Participants with current or history of excessive alcohol intake.
Where it's recruiting
Florida
Miami
Source: ClinicalTrials.gov · NCT07701993 · last updated 2026-08-05